The FDA has approved Takeda's Orzeyful (orexin agonist) for treating narcolepsy type 1 in adults, marking the first approval in a new class of sleep medicines that addresses the full range of narcolepsy symptoms. The approval is expected to reshape the treatment paradigm and launch a closely watched commercial drug race.
Researchers have developed a novel artificial intelligence model that analyzes data from routine polysomnography sleep studies to identify patients' long-term health risks, including cognitive decline. The study was published in Nature Communications.
Multiple breakthrough technologies for Alzheimer's detection are emerging, including a blood test that delivers results in 18 minutes, AI analysis of brain scans requiring minimal computing power, and machine learning that identifies dementia risk through sleep EEG patterns years before symptoms appear.
Frequent, long, or early-day naps in older adults are linked to higher mortality risk and may signal underlying conditions like cardiovascular disease, neurodegeneration, or sleep disorders, suggesting daytime sleep patterns could serve as an early warning sign of declining health.
Research from the University of Oulu suggests that large variations in bedtime during midlife may double the risk of cardiovascular events, highlighting the importance of consistent sleep schedules for heart health.
Medical professionals and neuroscientists are highlighting evidence-based strategies for maintaining brain health, including mental challenges, physical exercise, social engagement, and quality sleep. Research shows the brain begins shrinking around age 40, losing approximately 5% of volume per decade, making preventive habits increasingly important.
